CONCLUSION
In our study, although no apparent contribution of DEX on reducing
mortality and intubation rates has been demonstrated, a significantly
longer time before intubation was determined for this agent. Patients
with DM, CHF, and on insulin therapy less required DEX infusion whereas
patients treated with IVIG for severe COVID-19 more required DEX
infusion. Prospective randomized controlled trials with large sample
sizes are needed to decide whether DEX therapy has a positive effect on
mortality and intubation rates in patients with COVID-19.